<DOC>
	<DOCNO>NCT01800630</DOCNO>
	<brief_summary>Open-label Phase 1 sequential dose-escalation study 10 increase dos ( 3 6 patient ) determine characterize DLTs MTD gemcitabine HCl oral formulation ( D07001-F4 ) . Patients assign receive oral D07001-F4 Days 1 , 3 , 5 , 8 , 10 , 12 4 21-day cycle characterize safety tolerability .</brief_summary>
	<brief_title>Phase1 Study Gemcitabine HCl Oral Formulation ( D07001-F4 ) Patients With Advanced Solid Malignancies Malignant Lymphomas</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<criteria>Male female patient age 20 year old Signed date informed consent form Patients advance solid malignancy malignant lymphomas histological pathologic confirmation fail standard therapy standard therapy exist Both measurable nonmeasurable disease allow ( measurable disease per RECIST , version 1.1 , Revised Response Criteria Malignant Lymphoma [ Cheson criterion ] ) World Health Organization ( WHO ) performance status 0 2 At least 28 day elapse ( screen ) since patient 's prior systemic therapy , radiotherapy , major surgery ( exclude diagnostic biopsy venous access device placement ) Patient Absolute neutrophil count ( ANC ) ≥ 1500 cells/mm³ Platelet count ≥ 75,000 cells/mm³ Hemoglobin ≥ 9 g/dL . Patient adequate liver function , demonstrate : Aspartate transaminase ( AST ) alanine transaminase ( ALT ) ≤ 2.5*the upper limit normal ( ULN ) ( ≤ 5.0*ULN case liver metastasis ) Total bilirubin ≤ 1.5 mg/dL ( unless due Gilbert 's syndrome ) Albumin ≥ 2.5 g/dL International normalized ratio ( INR ) &lt; 1.5 Patient adequate renal function : Serum creatinine ≤ 1.5*ULN . Patient life expectancy &gt; 12 week . If woman childbearing potential , patient negative pregnancy test breast feeding . If woman childbearing potential , patient use medically acceptable form two barrier method ( e.g. , combination condom , diaphragm , intrauterine device ) , hormonal contraception ( estrogen progesterone agent ) one barrier method combination spermicide . Birth control require 1 month prior screening , duration study participation , 1 month end study ; female partner male patient also adhere similar birth control method Patient willing comply protocolrequired visit schedule visit requirement Patient receive fulldose ( therapeutic ) anticoagulation therapy . Patient intolerant allergic know hypersensitivity gemcitabine Patient clinically significant cardiovascular disease ( example : uncontrolled hypertension , unstable angina , congestive heart failure , New York Heart Association Grade 2 great ) . Patient uncontrolled serious cardiac arrhythmia . Patient known brain metastasis leptomeningeal metastasis . Patient unresolved toxicity ( &gt; Grade 1 ) previous anticancer therapy exception renal liver function require range describe inclusion criterion peripheral neuropathy acceptable resolve least grade 2 . Patient receive radiotherapy 10 Gy within 6 month screen . Patient history drug alcohol abuse within last year . Patient document cerebrovascular disease . Patient seizure disorder control medication ( base decision Investigator ) . Patient receive investigational agent within 28 day screen Patient receive systemic treatment infection within 14 day screen . Patient known human immunodeficiency virus ( HIV ) infection . Patient hepatitis B virus ( HBV ) and/or hepatitis C virus ( HCV ) infection medical history . Patient receive yellow fever vaccine live attenuate vaccine within last 4 week Patient serious medical condition , Investigator 's medical opinion , would preclude safe participation clinical trial . Patients gastrointestinal disease/prior surgery may interfere adequate oral therapy absorption Patients allogeneic stem cell transplantation Patients le 12 month autologous stem cell transplantation</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>